Streetbeat News

RXRX

Recursion Pharmaceuticals, Inc.

https://www.recursion.com

Industry

Biotechnology

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Open

6.89

Mkt cap

1.7B

Volume

10M

High

6.92

P/E Ratio

-4.23

52-wk high

15.74

Low

6.15

Div yield

N/A

52-wk low

5.88

Recursion Pharmaceuticals (NASDAQ:RXRX) reported Q3 earnings, missing estimated earnings by 13.16% with an EPS of $-0.43 versus an estimate of $-0.38. Revenue was down $2.63 million from the same period last year. Last quarter, the company also missed on EPS by $0.01, which was followed by a 5.02% drop in the share price the next day.

Portfolio Pulse from Benzinga Insights

November 09, 2023 | 1:00 pm

Recursion Pharmaceuticals (NASDAQ:RXRX) reported Q3 losses of $(0.43) per share, missing the analyst consensus estimate of $(0.39) by 10.26%. This is a 22.86% decrease from the same period last year. The company also reported quarterly sales of $10.53 million, missing the analyst consensus estimate of $12.87 million by 18.16%, a 19.96% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 1:00 pm

The article lists the stocks that have gained and lost the most in Friday's mid-day session. Among the gainers, Benson Hill, Inc. (BHIL) shares jumped 48.1% to $0.3740, and Seres Therapeutics, Inc. (MCRB) climbed 45.9% to $1.20 after posting a narrower-than-expected quarterly loss. Among the losers, Inseego Corp (INSG) shares fell 35% to $0.3370 after reporting worse-than-expected Q3 results, and Fortinet Inc (FTNT) shares fell 16.8% to $47.92 after reporting mixed Q3 results and issuing FY23 revenue guidance below estimates.

Portfolio Pulse from Lisa Levin

November 03, 2023 | 5:26 pm

Ark Invest, led by Cathie Wood, sold nearly $4 million worth of NVIDIA Corp shares, aligning with Wood's previous comments about the tech giant being expensive. The sale was made through the ARK Genomic Revolution ETF. Ark Invest also purchased shares of SomaLogic Inc, Recursion Pharmaceuticals, and Beam Therapeutics Inc.

Portfolio Pulse from Benzinga Neuro

October 03, 2023 | 2:07 am

Recursion Pharmaceuticals announced that Roche has exercised the validated small molecule option in a single area of oncology under their collaboration and license agreement. Roche will pay an option fee as per the agreement dated December 5, 2021.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 11:58 am

Several publicly traded companies are integrating artificial intelligence (AI) into their operations to catalyze transformations in the biotech and pharmaceutical sectors. These companies include Recursion Pharmaceuticals (RXRX), 23andMe (ME), Novartis (NVS), Roche (RHHBY), Pfizer (PFE), Johnson & Johnson (JNJ), Regeneron Pharmaceuticals (REGN), and Illumina (ILMN). The integration of AI is expected to enhance drug discovery, patient care, and other operations.

Portfolio Pulse from Steve Macalbry

September 11, 2023 | 5:27 pm

Needham analyst Gil Blum has reiterated a 'Buy' rating on Recursion Pharmaceuticals (NASDAQ:RXRX) and maintained a price target of $17.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2023 | 2:38 pm

Recursion (NASDAQ:RXRX), a clinical stage TechBio company, has completed the Phase 1 study for REC-3964 in healthy volunteers. The study achieved its primary objectives of assessing the safety, tolerability and pharmacokinetic profile of REC-3964, with no serious adverse events reported.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2023 | 12:01 pm

Ark Invest, led by Cathie Wood, sold $1.86 million worth of NVIDIA Corp shares through ARK Genomic Revolution ETF. This decision follows NVIDIA's recent Q2 earnings report and its performance in the AI sector. Ark Invest also made significant purchases of shares in CRISPR Therapeutics, Intellia Therapeutics, Accolade, and Recursion Pharmaceuticals.

Portfolio Pulse from Benzinga Neuro

August 25, 2023 | 2:57 am

Ark Invest, led by Cathie Wood, made significant trades on Tuesday, purchasing $8.1 million worth of Zoom shares and selling $1.02 million worth of Nvidia shares. The Zoom purchase comes after the company's strong Q2 earnings beat and the introduction of new AI features. The Nvidia sale comes amid various developments affecting the company's stock performance. Ark Invest also made trades involving CRISPR Therapeutics, Adaptive Biotechnologies, Recursion Pharmaceuticals, Intellia Therapeutics, Codexis, and Phenomex.

Portfolio Pulse from Benzinga Neuro

August 23, 2023 | 1:50 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.